title: Atypical cellular disorders.
abstract: Atypical cellular disorders are commonly considered part of the gray zone linking oncology to hematology and immunology. Although these disorders are relatively uncommon, they often represent significant clinical problems, provide an opportunity to understand basic disease mechanisms, and serve as model systems for the development of novel targeted therapies. This chapter focuses on such disorders. In Section I, Dr. Arceci discusses the pathogenesis of Langerhans cell histiocytosis (LCH) in terms of the hypothesis that this disorder represents an atypical myeloproliferative syndrome. The clinical manifestations and treatment of LCH in children and adults is discussed along with possible future therapeutic approaches based upon biological considerations. In Section II, Dr. Longley considers the molecular changes in the c-Kit receptor that form the basis of mastocytosis. Based on the location and function of c-Kit mutations, he develops a paradigm for the development of specific, targeted therapies. In Section III, Dr. Emanuel provides a review of the "mixed myeloproliferative and myelodysplastic disorders," including novel therapeutic approaches based on aberrant pathogenetic mechanisms. Taken together, these chapters should provide an overview of the biological basis for these disorders, their clinical manifestations, and new therapeutic approaches.
authors.affiliation: Div. of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Arceci
authors.forename: B Jack
authors.initials: BJ
authors.lastname: Longley
authors.forename: Peter D
authors.initials: PD
authors.lastname: Emanuel
mesh_terms: D000328:Adult; D001855:Bone Marrow Diseases / Q000628:therapy*; D002648:Child; D006646:Histiocytosis, Langerhans-Cell / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D006801:Humans; D008415:Mastocytosis / Q000188:drug therapy / Q000209:etiology; D009190:Myelodysplastic Syndromes / Q000628:therapy; D009196:Myeloproliferative Disorders / Q000628:therapy; D019009:Proto-Oncogene Proteins c-kit / Q000187:drug effects / Q000502:physiology*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors
chemical_list: D019009:Proto-Oncogene Proteins c-kit; D020794:Receptor Protein-Tyrosine Kinases